December 2010 Issue of MMM
This time last year, the majority of us were glad to see the back of 2009. The industry welcomed 2010 with an uncertain mix of ...
With a wave of mega-blockbusters set to expire in 2011 and with managed care increasingly in the driver's seat, pharmas will get another bite at ...
Launching a new pharmaceutical or biologic next year? Expect smaller sales than in years past and a gauntlet of more sophisticated payers, physicians and patients. ...
MM&M's Pipeline 2011 offers a short list of the so-called locks and long-shots to reach market over the next months and years. You'll find details ...
In October, Boehringer Ingelheim (BI) won FDA approval for Pradaxa, a blood thinner that reduces stroke risk in patients with non-valvular atrial fibrillation. As the ...
Looking back at the pharmaceutical marketing research professional conferences I have attended in 2010, I am sensing a bit of schizophrenia in the focus of ...
I and every other clinician who treats patients with the common blood thinner warfarin (Coumadin) have a problem.
A love-hate relationship for Coumadin is playing out online, say authors of a new report that may offer lessons for marketers of new blood-thinning products.
Biogen Idec and Elan's MS drug Tysabri realized a 15% increase in US revenues during the third quarter (compared with Q3 2009), a gain at ...
Allergan sales forces previously working on Glaxo-SmithKline headache drugs Imitrex and Amerge as part of a co-promotion will be reassigned to Botox, in support of ...
Featuring news about Alcon, SK&A and PLoS Medicine
Med Ed Report
Pri-Med launched its Open Network, an initiative designed to spur industry-wide innovation in the way professional med ed is developed, delivered and funded.
In the name of protecting patients, conflict-of-interest (COI) rules imposed by medical schools and public agencies are actually harming them, according to a report from ...
West Virginia University's four health profession schools have adopted new rules governing relations with industry vendors.
Featuring news about the NAAMECC (now NAMEC), Lighthouse Learning, Global Education Group and the Alliance for CME
The American Association for Cancer Research (AACR) will launch a new journal--Cancer Discovery--in April 2011.
Pharmacy Times launched a new title, Specialty Pharmacy Times, which will focus on policy, regulatory and legal issues, as well as product reviews, reimbursement and ...
Featuring news about Elsevier, the Canadian Cardiovascular Society, the Public Library of Science Medicine and San Lucas Medical Limited
Publishers of multispecialty and primary care titles enjoyed the largest ad-spend gains in a resurgent first-half 2010. Will things get more interesting for the specialty ...
Social networks are a "Wild West" of medical misinformation, a study has found. More than one in four comments on Facebook diabetes communities is promotional ...
MedImmune, together with Women's Professional Soccer and the American Youth Soccer Organization, launched an online campaign promoting flu immunization featuring soccer great Brandi Chastain.
Featuring news about the AMA, WebMD, the AARP and Consumer Reports Health
We all know chronic pain is a horrible thing, something people have tried to alleviate with every means possible-- herbal, physical, mystical, even pharmaceutical.
Novo Nordisk launched a consumer campaign for Victoza, emphasizing the product's ability to bring down blood sugar levels and body weight in patients with type ...
Bayer agreed to pay three states $3.3 million to settle charges that it made unsubstantiated claims in advertising that its One A Day Men's multivitamins ...
Electronic health records (EHRs) are poised to get a boost from the federal government's "meaningful use" incentive program next year, begging the question: can these ...
All Global, a Kantar-owned provider of healthcare panel data, has launched a service designed to offer, within 24 hours, analyzed responses to breaking drug news.
Contract sales giant PDI acquired digital agency Group DCA, seeking to bolster its non-personal promotion capabilities.
It's been a busy few weeks for the Adelphi unit of Omnicom's Diversified Agency Services (DAS) as the sub-holding company gobbled up two international agencies.
AbelsonTaylor named Nancy Drescher SVP, director of client services, responsible for running the firm's account services department.
Featuring news about GSW Worldwide, Stonefly Communications Group, DDB New York, Tribal DDB New York and Porter Novelli
The FDA's many initiatives on risk management are confusing to the industry--and the problem is, in many ways, of the agency's own making. We need ...
FDA commissioner Margaret Hamburg and principal deputy commissioner Joshua Sharfstein say they are concerned by how long it takes to make changes in the agency.
FDA's chief litigator said he is focusing on corporate chief executives for personal prosecution in cases of flagrant off-label product promotions.
As we finish 2010, one of the surprising healthcare marketing headlines has been the rapid ascendancy of mobile as a leading digital channel.
Biopharma is caught in a swirl of uncertainty greater than anything it has ever faced: legislative mandates, changing media consumption and patient and professional empowerment.
As our nation continues to debate how the healthcare system should be fixed, little attention has been paid to the need to better incorporate multiculturalism ...
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.